T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in nature! 🧵below nature.com/articles/s4158…

How specific are therapeutic monoclonal antibodies, really? In our new paper, Yile Dai led a collaboration with Adimab to profile 174 FDA-approved and clinical-stage mAbs against 6,172 human extracellular proteins. What we found surprised us.🧵 sciencedirect.com/science/articl…